Effects of vigabatrin on evoked potentials in dogs

Joseph C. Arezzo, C. E. Schroeder, M. S. Litwak, D. L. Steward

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The purpose of this study was to evaluate possible changes in brain morphology and evoked potentials associated with daily administration of 300 mg kg-1 vigabatrin in dogs. Somatosensory evoked potentials (SEP) and auditory evoked potentials (AEP) were recorded at baseline and weekly for 12 weeks of treatment and every 2 weeks for 17 weeks of recovery. Morphology was assessed immediately after treatment for two treated dogs and after recovery for the remaining five treated and two control dogs. Vigabatrin produced a significant slowing of the central transmission measure of the SEP with no alteration in the AEP. Vigabatrin was associated with microvacuolation in select regions of the brain including the fornix, septum, optic tract, hypothalamus, thalamus and cortex. In addition, some microglial proliferation was noted. Changes in SEP and the microvacuolation fully recovered after 17 weeks of treatment. The study confirms vigabatrin-induced microvacuolation in the dog and suggests these changes are associated with functional slowing of conduction in the somatosensory pathways.

Original languageEnglish (US)
JournalBritish Journal of Clinical Pharmacology
Volume27
Issue numberSUPPL. 1
StatePublished - 1989

Fingerprint

Vigabatrin
Evoked Potentials
Somatosensory Evoked Potentials
Dogs
Auditory Evoked Potentials
Brain Fornix
Thalamus
Hypothalamus
Brain

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Arezzo, J. C., Schroeder, C. E., Litwak, M. S., & Steward, D. L. (1989). Effects of vigabatrin on evoked potentials in dogs. British Journal of Clinical Pharmacology, 27(SUPPL. 1).

Effects of vigabatrin on evoked potentials in dogs. / Arezzo, Joseph C.; Schroeder, C. E.; Litwak, M. S.; Steward, D. L.

In: British Journal of Clinical Pharmacology, Vol. 27, No. SUPPL. 1, 1989.

Research output: Contribution to journalArticle

Arezzo, JC, Schroeder, CE, Litwak, MS & Steward, DL 1989, 'Effects of vigabatrin on evoked potentials in dogs', British Journal of Clinical Pharmacology, vol. 27, no. SUPPL. 1.
Arezzo, Joseph C. ; Schroeder, C. E. ; Litwak, M. S. ; Steward, D. L. / Effects of vigabatrin on evoked potentials in dogs. In: British Journal of Clinical Pharmacology. 1989 ; Vol. 27, No. SUPPL. 1.
@article{382358fa89f142cd8f7a7ddf9ef622f7,
title = "Effects of vigabatrin on evoked potentials in dogs",
abstract = "The purpose of this study was to evaluate possible changes in brain morphology and evoked potentials associated with daily administration of 300 mg kg-1 vigabatrin in dogs. Somatosensory evoked potentials (SEP) and auditory evoked potentials (AEP) were recorded at baseline and weekly for 12 weeks of treatment and every 2 weeks for 17 weeks of recovery. Morphology was assessed immediately after treatment for two treated dogs and after recovery for the remaining five treated and two control dogs. Vigabatrin produced a significant slowing of the central transmission measure of the SEP with no alteration in the AEP. Vigabatrin was associated with microvacuolation in select regions of the brain including the fornix, septum, optic tract, hypothalamus, thalamus and cortex. In addition, some microglial proliferation was noted. Changes in SEP and the microvacuolation fully recovered after 17 weeks of treatment. The study confirms vigabatrin-induced microvacuolation in the dog and suggests these changes are associated with functional slowing of conduction in the somatosensory pathways.",
author = "Arezzo, {Joseph C.} and Schroeder, {C. E.} and Litwak, {M. S.} and Steward, {D. L.}",
year = "1989",
language = "English (US)",
volume = "27",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
publisher = "Wiley-Blackwell",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Effects of vigabatrin on evoked potentials in dogs

AU - Arezzo, Joseph C.

AU - Schroeder, C. E.

AU - Litwak, M. S.

AU - Steward, D. L.

PY - 1989

Y1 - 1989

N2 - The purpose of this study was to evaluate possible changes in brain morphology and evoked potentials associated with daily administration of 300 mg kg-1 vigabatrin in dogs. Somatosensory evoked potentials (SEP) and auditory evoked potentials (AEP) were recorded at baseline and weekly for 12 weeks of treatment and every 2 weeks for 17 weeks of recovery. Morphology was assessed immediately after treatment for two treated dogs and after recovery for the remaining five treated and two control dogs. Vigabatrin produced a significant slowing of the central transmission measure of the SEP with no alteration in the AEP. Vigabatrin was associated with microvacuolation in select regions of the brain including the fornix, septum, optic tract, hypothalamus, thalamus and cortex. In addition, some microglial proliferation was noted. Changes in SEP and the microvacuolation fully recovered after 17 weeks of treatment. The study confirms vigabatrin-induced microvacuolation in the dog and suggests these changes are associated with functional slowing of conduction in the somatosensory pathways.

AB - The purpose of this study was to evaluate possible changes in brain morphology and evoked potentials associated with daily administration of 300 mg kg-1 vigabatrin in dogs. Somatosensory evoked potentials (SEP) and auditory evoked potentials (AEP) were recorded at baseline and weekly for 12 weeks of treatment and every 2 weeks for 17 weeks of recovery. Morphology was assessed immediately after treatment for two treated dogs and after recovery for the remaining five treated and two control dogs. Vigabatrin produced a significant slowing of the central transmission measure of the SEP with no alteration in the AEP. Vigabatrin was associated with microvacuolation in select regions of the brain including the fornix, septum, optic tract, hypothalamus, thalamus and cortex. In addition, some microglial proliferation was noted. Changes in SEP and the microvacuolation fully recovered after 17 weeks of treatment. The study confirms vigabatrin-induced microvacuolation in the dog and suggests these changes are associated with functional slowing of conduction in the somatosensory pathways.

UR - http://www.scopus.com/inward/record.url?scp=0024314487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024314487&partnerID=8YFLogxK

M3 - Article

VL - 27

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

IS - SUPPL. 1

ER -